Antiviral Potency Analysis and Functional Comparison of Consensus Interferon,Interferon-α2a and Pegylated Interferon-α2b against Hepatitis C virus Infection

Abstract

Background

Current treatments for chronic hepatitis C virus (HCV) employing pegylated interferon (PEG-IFN) plus ribavirin are successful in approximately 50% of patients. Consensus IFN (CIFN) is a recombinant type I IFN that has demonstrated efficacy where conventional therapy has failed. We evaluated the host cell antiviral response and anti-HCV actions induced by IFN-α2a, PEG-IFN-α2b or CIFN on cultured immortalized human hepatocytes, Huh7 human hepatoma cells and Huh7 cells that harboured genetically distinct HCV RNA replicons or were infected with HCV 2a.

Methods

Cultured cells were treated with each IFN at relevant dosing based upon the pharmacological attainable in vivo serum maximum IFN concentrations. Gene expression and antiviral properties were measured using protein, RNA and virus quantification assays.

Results

CIFN treatment maximally triggered Janus kinase signal transducer and activator of transcription signalling in association with enhanced IFN-stimulated gene (ISG) expression. Increased antiviral potency of CIFN was associated with enhancement of IFN-induced blockade upon viral protein synthesis, protection of the cellular IFN promoter stimulator-1 (IPS-1) protein from HCV proteolysis and reduced replication of an IFN-resistant HCV replicon variant. Microarray analyses revealed that CIFN treatment induced a distinct pattern of ISG expression in cultured hepatocytes compared with other IFNs.

Conclusions

CIFN exhibits increased anti-HCV potency over IFN-α2a and PEG-IFN through maximal and distinct induction of ISG expression and enhanced intracellular innate antiviral response, while protecting IPS-1 from HCV proteolysis. CIFN might offer a treatment regimen imparting translational control programmes and restoration of the retinoic acid-inducible gene-1/IPS-1 pathway and could be considered for previous treatment failures.

References

The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20–29.

Deutsch

, Hadziyannis

S.J.

Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008; 15: 2–11.

Blatt

L.M.

, Davis

J.M.

, Klein

S.B.

, Taylor

M.W.

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16: 489–499.

Tong

M.J.

, Reddy

K.R.

, Lee

W.M.

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26: 747–754.

Witthoeft

, Fuchs

, Ludwig

Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. World J Gastroenterol 2007; 13: 579–584.

Yasuda

, Miyata

Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile. Nippon Yakurigaku Zasshi 2002; 120: 421–426.

Sjogren

M.H.

, Sjogren

Jr. , Lyons

M.F.

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci 2007; 52: 1540–1547.

Miglioresi

, Bacosi

, Russo

Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res 2003; 27: 253–259.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

10.

McHutchison

J.G.

, Gordon

S.C.

, Schiff

E.R.

Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492.

11.

McHutchison

J.G.

Understanding hepatitis C. Am J Manag Care 2004; 10 Suppl 2: S21–S29.

12.

Feld

J.J.

, Hoofnagle

J.H.

Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967–972.

13.

Der

S.D.

, Zhou

, Williams

B.R.

, Silverman

R.H.

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide2 arrays. Proc Natl Acad Sci U S A 1998; 95: 15623–15628.

14.

Heim

M.H.

The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 1999; 19: 75–120.

15.

Stark

G.R.

, Kerr

I.M.

, Williams

B.R.

, Silverman

R.H.

, Schreiber

R.D.

How cells respond to interferons. Annu Rev Biochem 1998; 67: 227–264.

16.

Sen

G.C.

Viruses and interferons. Annu Rev Microbiol 2001; 55: 255–281.

17.

Kolumam

G.A.

, Thomas

, Thompson

L.J.

, Sprent

, Murali-Krishna

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005; 202: 637–650.

18.

Wang

, Pfugheber

, Sumpter

Jr. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003; 77: 3898–3912.

19.

Shimazaki

, Honda

, Kaneko

, Kobayashi

Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein. Hepatology 2002; 35: 199–208.

20.

Guo

J.T.

, Bichko

V.V.

, Seeger

Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516–8523.

21.

Prabhu

, Joshi

, Garry

R.F.

Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. Exp Mol Pathol 2004; 76: 242–252.

22.

Meylan

, Curran

, Hofmann

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167–1172.

23.

Loo

Y.M.

, Owen

D.M.

, Li

Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006; 103: 6001–6006.

24.

Foy

, Li

, Sumpter

Jr. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signalling. Proc Natl Acad Sci U S A 2005; 102: 2986–2991.

25.

Johnson

C.L.

, Owen

D.M.

, Gale

Jr. . Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 2007; 282: 10792–10803.

26.

Lau

D.T.

, Fish

P.M.

, Sinha

Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 2008; 47: 799–809.

27.

Hayashi

, Takehara

Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17–27.

28.

Ozes

O.N.

, Reiter

, Klein

, Blatt

L.M.

, Taylor

M.W.

A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992; 12: 55–59.

29.

Sumpter

Jr. , Loo

Y.M.

, Foy

Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79: 2689–2699.

30.

Blight

K.J.

, McKeating

J.A.

, Rice

C.M.

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 13001–13014.

31.

Ikeda

, Sugiyama

, Mizutani

Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res 1998; 56: 157–167.

32.

Pflugheber

, Fredericksen

, Sumpter

Jr. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A 2002; 99: 4650–4655.

33.

Foy

, Li

, Wang

Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145–1148.

34.

Sumpter

Jr. , Wang

, Foy

, Loo

Y.M.

, Gale

Jr. . Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol 2004; 78: 11591–11604.

35.

Tan

, Derrick

, Hong

Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. J Interferon Cytokine Res 2005; 25: 632–649.

36.

Fredericksen

, Akkaraju

G.R.

, Foy

Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol 2002; 15: 29–40.

37.

Applied Biosystems. User Bulletin No. 2. Relative quantification of gene expression. ABI PRISM 7700 Sequence Detection System. (Updated 2001.) Foster City, CA: Applied Biosystems 1997.

38.

Lenschow

D.J.

, Lai

, Frias-Staheli

IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 2007; 104: 1371–1376.

39.

Gale

Jr. , Foy

E.M.

Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939–945.

40.

Jiang

, Guo

, Xu

Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82: 1665–1678.

41.

Lohmann

, Korner

, Koch

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113.

42.

Cai

, Zhang

, Chang

K.S.

Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 2005; 79: 13963–13973.

43.

Farci

, Strazzera

, Alter

H.J.

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002; 99: 3081–3086.

44.

Yoneyama

, Kikuchi

, Natsukawa

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730–737.

45.

Neumann

A.U.

, Lam

N.P.

, Dahari

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–107.